Soft Tissue Sarcoma with Lung Metastasis Market
Once the systemic metastatic disease develops, the prognosis is typically poor. Patients with extremity sarcomas are more likely to develop the distant metastatic disease as the initial site of recurrence. In contrast, those with retroperitoneal and visceral sarcomas tend to present local recurrence.
The lung is the most frequent site of metastasis from soft-tissue sarcomas. Due to the relative resistance of sarcoma to either chemotherapy or radiotherapy, compared to other solid tumors, surgical management of pulmonary metastases has been a pivotal therapy in this disease.
Soft Tissue Sarcoma with Lung Metastasis Market has many histologic subtypes, and the malignancy can be low or high grade. Its treatments may include surgery, chemotherapy, radiation therapy, or a combination of these therapies.
There have been many attempts to improve the treatment outcome of locally advanced or locally relapsed disease by combining local treatment (surgery, radiotherapy) with systemic therapy, such as neoadjuvant (preoperative) or adjuvant (postoperative) chemotherapy.
There are only limited data supporting the use of such perioperative treatments in sarcoma.
Surgical resection of pulmonary metastases and chemotherapy are treatment options that have been employed, but many patients are poor candidates for these treatments for multiple host or tumor-related reasons
Metastasectomy and/or chemotherapy are the most common treatments offered to patients with metastatic sarcoma. Pulmonary metastasectomy, either video-assisted or through a formal thoracotomy, has been shown to increase overall survival in select populations of both osseous and soft tissue sarcoma patients.
While chemotherapy remains an important tool for the treatment of patients with metastatic sarcoma, there is mixed evidence on its survival impact. Furthermore, many older patients, as a result of various tumor- or comorbidity-related issues, are deemed poor candidates for surgery or chemotherapy.
Read More- Soft Tissue Sarcoma with Lung Metastasis Market Report
Comments
Post a Comment